title: Gastric helicobacter infection induces a Th2 phenotype but does not elevate serum cholesterol in mice lacking inducible nitric oxide synthase.
abstract: Persistent Helicobacter felis infection in (C57BL/6 x 129SvEv)F1 mice induces chronic gastritis. Expression of inducible nitric oxide synthase (iNOS) is upregulated in response to Helicobacter infection. In this study, 20 10-week-old iNOS-/- mice and 20 wild-type [(C57BL/6 x 129SvEv)F1] mice were infected with H. felis by oral gavage and were assessed histologically and serologically at 32 weeks postinfection. Equal numbers of uninfected controls were sham inoculated. The mice were scored for severity of gastric inflammation, hyperplasia, glandular atrophy, and mucous metaplasia in the corpus and for the level of helicobacter colonization. The immunoglobulin G1 (IgG1), IgG2a, and IgG2c antibody responses to H. felis were determined. As a secondary measure, serum cholesterol levels were assessed. iNOS-/- mice have a propensity for increased serum cholesterol, and although controversial, several human epidemiologic studies have demonstrated an association between Helicobacter infection and several risk factors for cardiovascular disease, including elevated serum cholesterol. Nevertheless, no differences in serum cholesterol levels were observed between the H. felis-infected and -uninfected iNOS-/- mice in this study. The uninfected animals had minimal to no gastric pathology. The gastric pathology scores for the infected animals were reduced significantly in the iNOS-deficient mice relative to those for the wild-type mice (all P <0.01). Helicobacter-infected iNOS-/- mice had chronic lymphoid infiltration and negligible to mild glandular atrophy and mucous metaplasia in the fundic mucosa, while H. felis-infected wild-type mice had severe atrophic and metaplastic mucosal changes. The atrophic gastritis in the infected wild-type mice, particularly the female mice, was also accompanied by greater granulocytic infiltration, antral hyperplasia, and diminished antral colonization, unlike that in the infected iNOS-/- mice. iNOS-/- mice developed significantly lower Th1-associated IgG2c antibody responses to H. felis (P <0.0003); the Th2-associated IgG1 responses were similar (P=0.09), suggesting a greater effect of the iNOS defect on Th1 responses. H. felis colonization was significantly greater in the iNOS-deficient mice. These findings are indicative of an impaired Th1 component of the H. felis-induced inflammatory response when the influence of iNOS is removed.
authors.affiliation: Division of Comparative Medicine, Massachusetts Institute of Technology, 77 Massachusetts Ave., Bldg. 16, Rm. 825C, Cambridge, MA 02139, USA.
authors.forename: Melanie
authors.initials: M
authors.lastname: Ihrig
authors.forename: Mark T
authors.initials: MT
authors.lastname: Whary
authors.forename: Charles A
authors.initials: CA
authors.lastname: Dangler
authors.forename: James G
authors.initials: JG
authors.lastname: Fox
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D002784:Cholesterol / Q000097:blood*; D005260:Female; D005756:Gastritis / Q000097:blood / Q000276:immunology* / Q000382:microbiology / Q000473:pathology; D016481:Helicobacter Infections / Q000097:blood / Q000276:immunology* / Q000382:microbiology / Q000473:pathology; D044922:Helicobacter felis / Q000276:immunology / Q000472:pathogenicity*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D019001:Nitric Oxide Synthase / Q000235:genetics* / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II; D013047:Specific Pathogen-Free Organisms; D013270:Stomach / Q000382:microbiology / Q000473:pathology; D018418:Th2 Cells / Q000276:immunology*
chemical_list: D000907:Antibodies, Bacterial; D002784:Cholesterol; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse
references.citation: J Biol Chem. 1999 Nov 19;274(47):33190-3
references.pmid: 10559188
references.citation: Free Radic Biol Med. 1999 Oct;27(7-8):781-9
references.pmid: 10515582
references.citation: Helicobacter. 2001 Mar;6(1):37-43
references.pmid: 11328364
references.citation: Dig Dis Sci. 2001 Apr;46(4):836-44
references.pmid: 11330421
references.citation: Atherosclerosis. 2001 May;156(1):103-7
references.pmid: 11369002
references.citation: Int Immunopharmacol. 2001 Aug;1(8):1397-406
references.pmid: 11515807
references.citation: Int Immunopharmacol. 2001 Aug;1(8):1407-20
references.pmid: 11515808
references.citation: Cancer Res. 2002 Feb 1;62(3):696-702
references.pmid: 11830522
references.citation: Infect Immun. 2002 Jun;70(6):3295-9
references.pmid: 12011029
references.citation: Mol Immunol. 2002 May;38(12-13):989-95
references.pmid: 12009578
references.citation: Helicobacter. 2002 Dec;7(6):342-8
references.pmid: 12485120
references.citation: Cancer Res. 2003 Mar 1;63(5):942-50
references.pmid: 12615707
references.citation: J Immunol. 2003 Apr 1;170(7):3782-9
references.pmid: 12646644
references.citation: Atherosclerosis. 2003 May;168(1):153-62
references.pmid: 12732399
references.citation: FEMS Immunol Med Microbiol. 2003 May 25;36(3):175-80
references.pmid: 12738388
references.citation: Dig Dis Sci. 2003 Apr;48(4):636-43
references.pmid: 12741449
references.citation: Biochem Pharmacol. 2003 May 15;65(10):1755-60
references.pmid: 12754112
references.citation: Aliment Pharmacol Ther. 2003 Jun;17 Suppl 2:75-81
references.pmid: 12786617
references.citation: Free Radic Biol Med. 2003 Jun 15;34(12):1621-30
references.pmid: 12788482
references.citation: Infect Immun. 2003 Jul;71(7):4163-6
references.pmid: 12819109
references.citation: Clin Biochem. 2003 Jul;36(5):359-65
references.pmid: 12849867
references.citation: J Pathol. 2003 Oct;201(2):303-11
references.pmid: 14517848
references.citation: Helicobacter. 2003;8(5):495-502
references.pmid: 14535996
references.citation: Curr Gastroenterol Rep. 2003 Dec;5(6):459-67
references.pmid: 14602053
references.citation: Am J Cardiol. 2004 Jan 15;93(2):219-20
references.pmid: 14715353
references.citation: Am J Physiol Gastrointest Liver Physiol. 2004 Mar;286(3):G361-6
references.pmid: 14766534
references.citation: Curr Top Med Chem. 2004;4(5):531-8
references.pmid: 14965304
references.citation: Gut. 2004 Sep;53(9):1250-5
references.pmid: 15306579
references.citation: Br Heart J. 1994 May;71(5):437-9
references.pmid: 8011406
references.citation: Gastroenterology. 1996 Jan;110(1):155-66
references.pmid: 8536852
references.citation: Immunology. 1997 Feb;90(2):205-11
references.pmid: 9135548
references.citation: Carcinogenesis. 1997 Sep;18(9):1841-5
references.pmid: 9328184
references.citation: BMJ. 1997 Nov 8;315(7117):1199-201
references.pmid: 9393222
references.citation: BMJ. 1998 Apr 11;316(7138):1130-2
references.pmid: 9552950
references.citation: J Biol Chem. 1998 Jun 5;273(23):14071-3
references.pmid: 9603902
references.citation: J Immunol Methods. 1998 Mar 15;212(2):187-92
references.pmid: 9672206
references.citation: Aliment Pharmacol Ther. 1998 Feb;12 Suppl 1:83-90
references.pmid: 9701006
references.citation: Nitric Oxide. 1998;2(3):187-92
references.pmid: 9731636
references.citation: Circulation. 1998 Sep 1;98(9):845-50
references.pmid: 9738638
references.citation: Circulation. 1998 Sep 29;98(13):1286-90
references.pmid: 9751676
references.citation: Atherosclerosis. 1999 Jan;142(1):207-10
references.pmid: 9920523
references.citation: Ann N Y Acad Sci. 1998 Nov 17;859:96-111
references.pmid: 9928373
references.citation: J Clin Microbiol. 1999 May;37(5):1651
references.pmid: 10203549
references.citation: Aliment Pharmacol Ther. 1999 Mar;13 Suppl 1:13-8
references.pmid: 10209682
references.citation: Clin Cancer Res. 1999 Jun;5(6):1411-5
references.pmid: 10389926
references.citation: J Immunol. 1999 Aug 1;163(3):1490-7
references.pmid: 10415051
references.citation: Age Ageing. 1999 Jul;28(4):367-71
references.pmid: 10459790
references.citation: Infect Immun. 1999 Oct;67(10):5151-6
references.pmid: 10496889
references.citation: Nat Med. 2000 May;6(5):536-42
references.pmid: 10802709